Products
Nonacog alfa is commercially available as an injectable (BeneFIX). It has been approved in many countries since 1998.
Structure and properties
Nonacog alfa is a recombinant blood clotting factor IX produced by biotechnological methods. It is a glycoprotein with 415 amino acids and a molecular mass of 55 kDa. Nonacog alfa is a vitamin K-dependent serine protease.
Effects
Nonacog alfa (ATC B02BD09) replaces the missing natural blood clotting factor IX and enables blood clotting. As a result, bleeding is prevented.
Indications
For prevention and treatment of bleeding in patients with hemophilia B (congenital factor IX deficiency).
Dosage
According to the SmPC. The drug is injected slowly intravenously.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Interactions
There are no known drug-drug interactions.
Adverse effects
The most common possible adverse effects include administration site reactions, neutralizing antibodies to factor IX, dizziness, headache, taste changes, drowsiness, and nausea. Rarely, hypersensitivity reactions may occur.
